Cue Biopharma Inc
Research Cue Biopharma Inc (CUE) on Bullrun: market cap USD 139.94M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCUE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 139.94M
- Financial periodQ1 2026
- RevenueUSD 5.69M
- Net income-USD 19.52M
- Free cash flow-USD 11.06M
Valuation Snapshot
latest market cap is USD 139.94M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 27.47M | -USD 26.60M | -USD 21.86M | n/a | -0.28 | USD 27.14M | USD 4.20M | USD 26.43M |
| FY2024 | USD 9.29M | -USD 40.67M | -USD 36.40M | n/a | -0.72 | USD 22.46M | USD 37.00K | USD 17.50M |
| FY2023 | USD 5.49M | -USD 50.73M | -USD 39.96M | n/a | -1.11 | USD 48.51M | USD 8.20M | USD 37.09M |
| FY2022 | USD 1.25M | -USD 53.01M | -USD 41.98M | n/a | -1.49 | USD 51.61M | USD 10.04M | USD 65.68M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 139.94M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 29.47M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 67.38M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 119.12M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 122.68M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 364.20M | n/a | n/a | n/a |
About Cue Biopharma Inc
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cue Biopharma Inc's market cap?
Cue Biopharma Inc's market capitalization is USD 139.94M.
What does Cue Biopharma Inc do?
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance.